Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JP Morgan Reinstates Neutral on Agios Pharmaceuticals, Announces $46 Price Target

Author: Benzinga Newsdesk | June 13, 2024 05:07pm
JP Morgan analyst Tessa Romero reinstates Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and announces $46 price target.

Posted In: AGIO